News

At the same time, the company has received scientific advice from the European Medicines Agency (EMEA) on Anthera’s European development strategy for varespladib. Anthera has said that the

Under the agreement, Miraculins will also retain Mount Sinai Services (MSS) to provide laboratory and testing services for future clinical trials and regulatory clearance or approval studies involving

Formerly know as BioSign, Visensia’s automated early warning technology fuses up to five vital signs – heart rate, respiration rate, body temperature, oxygen saturation and blood pressure –

This first Phase I clinical trial will assess the safety of PMX-60056. The protocol for this study involves a dose-escalation study in healthy volunteers in which each subject

Biothorpe’s intellectual property portfolio includes the therapeutic use of siRNA and other oligonucleotides directed at Syk kinase. Biothorpe intends to license its intellectual property for the treatment of

Cryo-Cell has formalized agreements with C’elle distribution partners in the UK, Ireland, Italy, Greece, Venezuela and Panama. Cryo-Cell’s technology license partner, LifeCell Private Ltd has previously announced plans

The protocol is based on information from a detailed analysis of the overall Prolacria clinical trial data to date, including Inspire’s Phase III trials and recently completed pilot

Under the agreement, Critical Outcome Technologies (COTI) will retain intellectual property ownership of its drug candidates, including any data resulting from preclinical experiments. COTI will manage the synthetic

Grupo Ricap is a third-party manufacturer of infant formula and Martek’s life’sDHA & life’sARA will initially be available in infant formula products produced for a large chain of